Αρχική / Δημοσιεύσεις ERN- RITA

Δημοσιεύσεις ERN- RITA

Δημοσιεύσεις

1: Moosmann T, Veraar C, Brunner J, Fraedrich G, Frech A, Horninger W, Ratzinger

G, Streif W, Teuchner B, Willeit J, Zlamy M, De Zordo T, Schirmer M. Differential

clinical presentation of Adamantiades-Behçet’s disease in non-endemic and endemic

areas: retrospective data from a Middle-European cohort study. Int J Rheum Dis.

2018 Dec;21(12):2151-2157. doi: 10.1111/1756-185X.13306. Epub 2018 Apr 17. PubMed

PMID: 29664210.

 

2: Protogerou AD, Nasothimiou EG, Sfikakis PP, Tzioufas AG. Non-invasive vascular

biomarkers in patients with Behçet’s disease: review of the data and future

perspectives. Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):100-107. Epub 2017

Oct 6. Review. PubMed PMID: 29148423.

 

3: Argyropoulou OD, Protogerou AD, Sfikakis PP. Accelerated atheromatosis and

arteriosclerosis in primary systemic vasculitides: current evidence and future

perspectives. CurrOpinRheumatol. 2018 Jan;30(1):36-43. doi:

10.1097/BOR.0000000000000453. Review. PubMed PMID: 29040156.

 

4: Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K,

Tektonidou M, Markomichelakis N. Brief Report: Drug-Free Long-Term Remission in

Severe Behçet’s Disease Following Withdrawal of Successful Anti-Tumor Necrosis

Factor Treatment. Arthritis Rheumatol. 2017 Dec;69(12):2380-2385. doi:

10.1002/art.40235. Epub 2017 Nov 8. PubMed PMID: 28834393.

 

5: Arida A, Sfikakis PP. Anti-cytokine biologic treatment beyond anti-TNF in

Behçet’s disease. Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S149-55. Epub

2014 Sep 30. Review. PubMed PMID: 25268669.

 

6: Vaiopoulos AG, Sfikakis PP, Kanakis MA, Vaiopoulos G, Kaklamanis PG.

Gastrointestinal manifestations of Behçet’s disease: advances in evaluation and

management. Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S140-8. Epub 2014 Sep

  1. Review. PubMed PMID: 25268668.

 

7: Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A,

Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji

  1. Diagnosis and management of Neuro-Behçet’s disease: international consensus

recommendations. J Neurol. 2014 Sep;261(9):1662-76. doi:

10.1007/s00415-013-7209-3. Epub 2013 Dec 24. Review. PubMed PMID: 24366648;

PubMed Central PMCID: PMC4155170.

 

8: Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab

for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15

patients. Am J Ophthalmol. 2012 Sep;154(3):534-541.e1. doi:

10.1016/j.ajo.2012.03.035. Epub 2012 Jul 11. PubMed PMID: 22789563.

 

9: Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s

disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011

Aug;41(1):61-70. doi: 10.1016/j.semarthrit.2010.09.002. Epub 2010 Dec 17. Review.

PubMed PMID: 21168186.

 

10: Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P,

Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis

attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford).

2011 Mar;50(3):593-7. doi: 10.1093/rheumatology/keq366. Epub 2010 Nov 21. PubMed

PMID: 21097877.

 

11: Sfikakis PP. The first decade of biologic TNF antagonists in clinical

practice: lessons learned, unresolved issues and future directions. Curr Dir

Autoimmun. 2010;11:180-210. doi: 10.1159/000289205. Epub 2010 Feb 18. Review.

PubMed PMID: 20173395.

 

12: Arida A, Vaiopoulos G, Markomichelakis N, Kaklamanis P, Sfikakis PP. Are

clusters of patients with distinct clinical expression present in Behçet’s

disease? Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S48-51. PubMed PMID:

19796533.

 

13: Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH,

Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N,

Yurdakul S, Yazici H. Management of Behçet disease: a systematic literature

review for the European League Against Rheumatism evidence-based recommendations

for the management of Behçet disease. Ann Rheum Dis. 2009 Oct;68(10):1528-34.

doi: 10.1136/ard.2008.087957. Epub 2008 Apr 17. Review. PubMed PMID: 18420940.

 

14: Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH,

Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N,

Yurdakul S, Yazici H; EULAR Expert Committee. EULAR recommendations for the

management of Behçet disease. Ann Rheum Dis. 2008 Dec;67(12):1656-62. doi:

10.1136/ard.2007.080432. Epub 2008 Jan 31. PubMed PMID: 18245110.

 

15: Elezoglou A, Kafasi N, Kaklamanis PH, Theodossiadis PG, Kapsimali V, Choremi

E, Vaiopoulos G, Sfikakis PP. Infliximab treatment-induced formation of

autoantibodies is common in Behçet’s disease. Clin Exp Rheumatol. 2007

Jul-Aug;25(4 Suppl 45):S65-9. PubMed PMID: 17949554.

 

16: Protogerou AD, Sfikakis PP, Stamatelopoulos KS, Papamichael C, Aznaouridis K,

Karatzis E, Papaioannou TG, Ikonomidis I, Kaklamanis P, Mavrikakis M, Lekakis J.

Interrelated modulation of endothelial function in Behcet’s disease by clinical

activity and corticosteroid treatment. Arthritis Res Ther. 2007;9(5):R90. PubMed

PMID: 17845731; PubMed Central PMCID: PMC2212573.

 

17: Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A,

Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis

P, Yazici H. Anti-TNF therapy in the management of Behcet’s disease–review and

basis for recommendations. Rheumatology (Oxford). 2007 May;46(5):736-41. Epub

2007 Apr 2. Review. PubMed PMID: 17403712.

 

18: Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis

induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.

Arthritis Rheum. 2005 Aug;52(8):2513-8. PubMed PMID: 16052599.

 

19: Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S,

Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema

associated with uveitis. Am J Ophthalmol. 2004 Oct;138(4):648-50. PubMed PMID:

15488796.

 

20: Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG,

Papaefthimiou S, Markomichelakis N. Infliximab for recurrent, sight-threatening

ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004 Mar

2;140(5):404-6. PubMed PMID: 14996689.

 

21: Katsiari CG, Theodossiadis PG, Kaklamanis PG, Markomichelakis NN, Sfikakis

  1. Successful long-term treatment of refractory Adamantiades-Behçet’s disease

(ABD) with infliximab: report of two patients. Adv Exp Med Biol. 2003;528:551-5.

PubMed PMID: 12918762.

 

22: Elezoglou AV, Sfikakis PP, Vaiopoulos G, Kapsimali V, Kaklamanis PG. Serum

levels of soluble TNF-alpha receptor-II (P75), circulating gammadelta T-cells and

Adamantiades-Behçet’s disease activity. Adv Exp Med Biol. 2003;528:261-5. PubMed

PMID: 12918703.

 

23: Sfikakis PP. Behçet’s disease: a new target for anti-tumour necrosis factor

treatment. Ann Rheum Dis. 2002 Nov;61 Suppl2:ii51-3. Review. PubMed PMID:

12379622; PubMed Central PMCID: PMC1766720.

 

24: Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN.

Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet.

2001 Jul 28;358(9278):295-6. PubMed PMID: 11498218.

 

25: Vaiopoulos G, Sfikakis PP, Hatzinikolaou P, Stamatelos G, Kaklamanis P.

Adamantiadis-Behçet’s disease in sisters. Clin Rheumatol. 1996 Jul;15(4):382-4.

PubMed PMID: 8853173.

 

 

Top